Table 4.
Demographic, clinical, and laboratory characteristics of RA patients with and without renal dysfunction based on BSA-indexed eGFR values
| With renal dysfunctiona (n = 355) | Without renal dysfunctiona (n = 1553) | p valueb | |
|---|---|---|---|
| Age, years, mean (SD) | 73.1 (9.6) | 61.0 (12.7) | < 0.001 |
| ≥ 65 years, patient number (%) | 294 (82.8) | 652 (42.0) | < 0.001 |
| Male/female | 60/295 | 290/1263 | 0.49 |
| RA duration, years, mean (SD) | 12.7 (11.2) | 10.3 (9.0) | < 0.001 |
| ≤ 3 years, patient number (%) | 55 (15.5) | 345 (22.2) | 0.005 |
| Anti-CCP (+), patient number (%) | 280 (78.9) | 1206 (77.7) | 0.67 |
| Stage III/IV, patient number (%) | 187 (52.7) | 724 (46.6) | 0.045 |
| CDAI, mean (SD) | 6.3 (6.7) | 6.2 (6.6) | 0.84 |
| HAQ, mean (SD) | 0.59 (0.79) | 0.38 (0.60) | < 0.001 |
| ≥ 1.0, patient number (%) | 87 (24.5) | 244 (15.7) | < 0.001 |
| < 0.25, patient number (%) | 157 (44.2) | 514 (33.1) | < 0.001 |
| Serum CRP, mg/dl, mean (SD) | 0.47 (1.31) | 0.33 (0.81) | 0.014 |
| BMI, kg/m2, mean (SD) | 22.7 (3.4) | 22.5 (3.7) | 0.31 |
| > 25, patient number (%) | 79 (22.3) | 328 (21.1) | 0.67 |
| < 18.5, patient number (%) | 29 (8.2) | 167 (10.8) | 0.18 |
| Hypertension, patient number (%) | 216 (60.1) | 408 (26.3) | < 0.001 |
| NIDDM, patient number (%) | 61 (17.2) | 133 (8.6) | < 0.001 |
| Serum LDL-C, mg/dl, mean (SD) | 112.4 (31.3) | 111.2 (28.2) | 0.50 |
| ≥ 140 mg/dl, patient number (%) | 61 (17.4) | 213 (13.6) | 0.094 |
| Current/ex-smokers, number (%) | 64 (18.0) | 338 (21.8) | 0.13 |
| Use of biologics, patient number (%) | 135 (38.0) | 506 (32.6) | 0.054 |
| MTX use, patient number (%) | 141 (39.4) | 844 (54.3) | < 0.001 |
| Dose, mg/week, mean (SD) | 6.7 (3.0) | 8.4 (3.6) | < 0.001 |
| Cumulative dose, g, median (IQR) | 2.7 (1.3–4.3) | 2.8 (1.2–4.7) | 0.22 |
| NSAID use, patient number (%) | 91 (25.6) | 397 (25.6) | 1.00 |
| ASAS-NSAID score, mean (SD) | 49.8 (19.9) | 48.2 (21.2) | 0.50 |
| Concurrent steroids, number (%) | 54 (15.2) | 183 (11.8) | 0.094 |
| Steroid use, patient number (%) | 127 (35.8) | 458 (29.5) | 0.022 |
| Dose, mg/day, mean (SD) | 3.0 (1.9) | 2.9 (2.1) | 0.80 |
| Cumulative dose, g, median (IQR) | 5.0 (1.5–14.6) | 3.2 (0.8–9.5) | < 0.001 |
RA rheumatoid arthritis, eGFR estimated glomerular filtration rate, anti-CCP anti-citrullinated peptide antibodies, CDAI clinical disease activity index, HAQ health assessment questionnaire, CRP C-reactive protein, BMI body mass index, NIDDM non-insulin-dependent diabetes mellitus, LDL-C low-density lipoprotein cholesterol, MTX methotrexate, NSAIDs nonsteroidal anti-inflammatory drugs, ASAS Assessment of Spondyloarthritis International Society, SD standard deviation, IQR interquartile range
aDefined as a BSA-indexed eGFR <60 ml/min/1.73 m2. Average values of two measurements of eGFR taken over a 3-month interval were used
bComparison between RA patients with renal dysfunction and those without